Ben-Arye Eran, Samuels Noah, Schiff Elad, Raz Orit Gressel, Sharabi Ilanit Shalom, Lavie Ofer
Integrative Oncology Program, The Oncology Service, Lin Medical Center, Western Galilee District, Clalit Health Services, 35 Rothschild St., Haifa, Israel.
Complementary and Traditional Medicine Unit, Department of Family Medicine, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Support Care Cancer. 2015 Dec;23(12):3411-9. doi: 10.1007/s00520-015-2690-0. Epub 2015 Mar 10.
Integrative oncology incorporates complementary medicine (CM) therapies in patients with cancer. We explored the impact of an integrative oncology therapeutic regimen on quality-of-life (QOL) outcomes in women with gynecological cancer undergoing chemotherapy.
A prospective preference study examined patients referred by oncology health care practitioners (HCPs) to an integrative physician (IP) consultation and CM treatments. QOL and chemotherapy-related toxicities were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire, at baseline and at a 6-12-week follow-up assessment. Adherence to the integrative care (AIC) program was defined as ≥ 4 CM treatments, with ≤ 30 days between each session.
Of 128 patients referred by their HCP, 102 underwent IP consultation and subsequent CM treatments. The main concerns expressed by patients were fatigue (79.8%), gastrointestinal symptoms (64.6%), pain and neuropathy (54.5 %), and emotional distress (45.5%). Patients in both AIC (n = 68) and non-AIC (n = 28) groups shared similar demographic, treatment, and cancer-related characteristics. ESAS fatigue scores improved by a mean of 1.97 points in the AIC group on a scale of 0-10 and worsened by a mean of 0.27 points in the non-AIC group (p = 0.033). In the AIC group, MYCAW scores improved significantly (p < 0.0001) for each of the leading concerns as well as for well-being, a finding which was not apparent in the non-AIC group.
An IP-guided CM treatment regimen provided to patients with gynecological cancer during chemotherapy may reduce cancer-related fatigue and improve other QOL outcomes.
整合肿瘤学将补充医学（CM）疗法应用于癌症患者。我们探讨了一种整合肿瘤学治疗方案对接受化疗的妇科癌症女性患者生活质量（QOL）结果的影响。
一项前瞻性偏好研究对肿瘤医疗保健从业者（HCP）转介至整合医学医生（IP）咨询及CM治疗的患者进行了检查。在基线以及6 - 12周的随访评估中，使用埃德蒙顿症状评估量表（ESAS）和自我测量担忧与幸福感（MYCAW）问卷对QOL和化疗相关毒性进行了评估。整合照护（AIC）计划的依从性定义为接受≥4次CM治疗，且每次治疗间隔≤30天。
在128名由其HCP转介的患者中，102名接受了IP咨询及后续的CM治疗。患者表达的主要担忧包括疲劳（79.8%）、胃肠道症状（64.6%）、疼痛和神经病变（54.5%）以及情绪困扰（45.5%）。AIC组（n = 68）和非AIC组（n = 28）的患者在人口统计学、治疗及癌症相关特征方面相似。AIC组的ESAS疲劳评分在0 - 10分的量表上平均改善了1.97分，而非AIC组平均恶化了0.27分（p = 0.033）。在AIC组中，MYCAW评分在每个主要担忧以及幸福感方面均显著改善（p < 0.0001），这一结果在非AIC组中并不明显。
在化疗期间为妇科癌症患者提供的IP指导下的CM治疗方案可能会减轻癌症相关疲劳并改善其他QOL结果。
